Nuclear estrogen receptors co-activation mechanisms

Current Medicinal Chemistry

Volumn 20, Issue 27, 2013, Pages 3317-3338

  Skrzypczak, M ^a   Kapka Skrzypczak, L ^b,c   Cyranka, M ^b   Treeck, O ^d   Wrobel A ^a   Matosiuk, D ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^c UNIVERSITY OF INFORMATION TECHNOLOGY AND MANAGEMENT   (Poland)

^d UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Aromatic hydrocarbon receptor; Cyclase kinases; Estrogen co activators; Estrogen co repressors; Estrogen receptor related proteins; Estrogene receptors; Histone acetyltransferase; Histone deacetylase; Kinase inhibitors; MAPK; Protein kinases

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; DNA; ESTROGEN RECEPTOR; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; ICI 164 384; MITOGEN ACTIVATED PROTEIN KINASE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PROTEIN KINASE C; RALOXIFENE; RAS PROTEIN; SERINE; TAMOXIFEN; THREONINE; UNCLASSIFIED DRUG;

ARTICLE; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE;

EID: 84883302203     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990006     Document Type: Article

References (264)

1. Ethier, S.P. Growth factor synthesis and human breast cancer progression. J. Natl. Cancer. Inst., 1995, 87, 964-73.
2. Kurita, T.; Young, P.; Brody, J.R.; Lydon, J.P.; O'Malley, B.W.; Cunha, G.R. Stromal progesterone receptors mediate the inhibitory effects of progesterone on estrogen-induced uterine epithelial cell deoxyribonucleic acid synthesis. Endocrinology, 1998, 139, 4708-13.
3. McDonnell, D.P. Mining the complexities of the estrogen signaling pathways for novel therapeutics. Endocrinology, 2003, 144, 4237-40.
4. Omoto, Y.; Kobayashi, Y.; Nishida, K.; Tsuchiya, E.; Eguchi, H.; Nakagawa, K.; Ishikawa, Y.; Yamori, T.; Iwase, H.; Fujii, Y.; Warner, M.; Gustafsson, J.A.; Hayashi, S.I. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem. Biophys. Res. Commun., 2001, 285, 340-7.
5. Jensen, E.V.; Jordan, V.C. The estrogen receptor: a model for molecular medicine. Clin. Cancer. Res., 2003, 9, 1980-9.
6. Jensen, E.V.; Mohla, S.; Brecher, P.I.; DeSombre, E.R. Estrogen receptor transformation and nuclear RNA synthesis. Adv. Exp. Med. Biol., 1973, 36, 60-79.
7. Pettersson, K.; Svensson, K.; Mattsson, R.; Carlsson, B.; Ohlsson, R.; Berkenstam, A. Expression of a novel member of estrogen response element-binding nuclear receptors is restricted to the early stages of chorion formation during mouse embryogenesis. Mech. Dev., 1996, 54, 211-23.
8. Abney, T.O. The potential roles of estrogens in regulating Leydig cell development and function: Steroids, 1999, 64, 610-7.
9. Aceitero, J,; Llanero, M.; Parrado, R.; Pena, E.; Lopez-Beltran, A. Neonatal exposure of male rats to estradiol benzoate causes rete testis dilation and backflow impairment of spermatogenesis. Anat. Rec., 1998, 252, 17-33.
10. Ali, S.; Coombes, R.C. Estrogen receptor alpha in human breast cancer: occurrence and significance. J. Mammary Gland Biol. Neoplasia, 2000, 5, 271-81.
11. Ali, S.; Metzger, D.; Bornert, J.M.; Chambon, P. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J., 1993, 12, 1153-60.
12. Amant, F.; Moerman, P.; Neven, P.; Timmerman, D.; Van Limbergen, E.; Vergote, I. Endometrial cancer. Lancet, 2005, 366 (9484), 491-505.
13. Andersen, T.I.; Heimdal, K.R.; Skrede, M.; Tveit, K.; Berg, K.; Borresen, A.L. Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility. Hum. Genet., 1994, 94, 665-70.
14. Pilardo, E.J.; Quinn, J.A.; Blande, K.I.; Frackelton, A.R. Jr. Estrogen-induced activation of Erk1/2-1 Erk1/2-2 requires the G proteincoupled receptor homolog, GPR-30, and occurs via trans-activation of the epidermal growth factor receptor through release of HBEGF. Mol. Endocrinol. 2000, 14, 1649-1660.
15. Couse, J.F.; Korach, K.S. Estrogen receptor null mice: what have we learned and where will they lead us. Endocr. Rev. 1999, 20, 358-417.
16. Nilsson, S.; Makele, S.; Treuter, E.; Tujague, M.; Thomsen, J.; Andersson, G.; Enmark, E.; Pettersson, K.; Warner, M.; Gustafsson, J.A. Mechanism of estrogen action. Physiol. Rev. 2001, 31, 1535-1565.
17. Mutter, G.L.; Boynton, K.A.; Faquin, W.C.; Ruiz, R.E.; Jovanovic, A.S. Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer. Cancer Res. 1996, 56(19), 4483-6.
18. Osborne, C.K.; Boldt, D.H.; Clark, G.M.; Trent, J.M. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res. 1983, 43, 3583-5.
19. Jensen, E.V.; DeSombre, E.R. Mechanism of action of the female sex hormones. Annu. Rev. Biochem. 1972, 41, 203-30.
20. Matsuzaki, S.; Fukaya, T.; Suzuki, T.; Murakami, T.; Sasano, H.; Yajima, A. Oestrogen receptor alpha and beta mRNA expression in human endometrium throughout the menstrual cycle. Mol. Hum. Reprod. 1999, 5, 559-64.
21. Shughrue, P.J.; Lane, M.V.; Scrimo, P.J.; Merchenthaler, I. Comparative distribution of estrogen receptor-alpha (ER-alpha) and beta (ER-beta) mRNA in the rat pituitary, gonad, and reproductive tract. Steroids 1998, 63, 498-504.
22. Simpkins, S.B.; Peiffer-Schneider, S.; Mutch, D.G.; Gersell, D.; Goodfellow, P.J. PTEN mutations in endometrial cancers with 10q LOH: additional evidence for the involvement of multiple tumor suppressors. Gynecol. Oncol. 1998, 71(3), 391-5.
23. Takama, F.; Kanuma, T.;Wang, D.; Kagami, I.; Mizunuma, H. Oestrogen receptor β expression and depth of myometrial invasion in human endometrial cancer. Br. J. Cancer 2001, 84, 545-9.
24. Duggan, B.D.; Felix, J.C.; Muderspach, L.I.; Tourgeman, D.; Zheng, J.; Shibata D. Microsatellite instability in sporadic endometrial carcinoma. J. Natl. Cancer. Inst. 1994, 86(16),;1216-21.
25. Eccles, M.R.; He, S.; Legge, M.; Kumar, R.; Fox, J.; Zhou, C.; French, M.; Tsai, R.W. PAX genes in development and disease: the role of PAX2 in urogenital tract development. Int. J. Dev. Biol. 2002, 46(4), 535-44.
26. Eddy, E.M.; Washburn, T.F.; Bunch, D.O.; Goulding, E.H.; Gladen, B.C.; Lubahn, D.B.; Korach, K.S. Targeted disruption of the estrogen receptor gene in male mice causes alteration of spermatogenesis and infertility. Endocrinology 1996, 137, 4796-805.
27. Ekena, K.; Katzenellenbogen, J.A.; Katzenellenbogen, B.S. Determinants of ligand specificity of estrogen receptor-alpha: estrogen versus androgen discrimination. J. Biol. Chem. 1998, 273, 693-9.
28. Carreau, S.; Genissel, C.; Bilinska, B.; Levallet, J. Sources of oestrogen in the testis and reproductive tract of the male. Int. J. Androl. 1999, 22, 211-23.
29. Clarke, R.; Brunner, N.; Thompson, E.W.; Glanz, P.; Katz, D.; Dickson, R.B.; Lippman, M.E. The inter-relationships between ovarian-independent growth, tumorigenicity, invasiveness and antiestrogen resistance in the malignant progression of human breast cancer. J. Endocrinol. 1989, 122, 331-40.
30. Collins, F.; MacPherson, S.; Brown, P.; Bombail, V.; Williams, A.R.; Anderson, R.A.; Jabbour, H.N.; Saunders, P.T. Expression of oestrogen receptors, ERα, ERβ, and ERβ variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERα. BMC Cancer. 2009, 16, 9:330.
31. Fuqua, S.A.; Fitzgerald, S.D.; Chamness, G.C.; Tandon, A.K.; McDonnell, D.P.; Nawaz, Z.; O'Malley, B.W.; McGuire, W.L. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 1991, 51, 105-109.
32. Iwase, H.; Zhang, Z.; Omoto, Y.; Sugiura, H.; Yamashita, H.; Toyama, T.; Iwata, H.; Kobayashi, S. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Chemother. Pharmacol. 2003, 52(Suppl 1), S34-8.
33. Saunders, P.T.K.; Millar, M.R.; MacPherson, S.; Irvin, D.S.; Groome, N.P.; Evans, L.R.; Sharpe, R.M.; Scobie, G.A. ERβ1 and the ERβ2 splice variant (ERβcx/β2) are expressed in distinct cell populations in the adult human testis. J. Clinic. Endocrin. Metabol. 2002, 87 (6), 2706-2715.
34. Skrzypczak, M.; Bieche, I.; Szymczak, S.; Tozlu, S.; Lewandowski, S.; Girault, I.; Radwanska, K.; Szczylik, C.; Jakowicki, J.A.; Lidereau, R.; Kaczmarek, L. Evaluation of mRNA expression of estrogen receptor b and its isoforms in human normal and neoplastic endometrium. Int. J. Cancer 2004, 110, 783-787.
35. Fisher, J.S.; Turner, K.J.; Fraser, H.M.; Saunders, P.T.; Brown, D.; Sharpe, R.M. Immunoexpression of aquaporin-1 in the efferent ducts of the rat and marmoset monkey during development, its modulation by estrogens, and its possible role in fluid resorption. Endocrinology 1998, 139, 3935-45.
36. Gorski, J.; Welshons, W.; Sakai, D. Remodeling the estrogen receptor model. Mol. Cell Endocrinol. 1984, 36, 11-5.
37. Gusberg, S.B. Estrogen and endometrial cancer: an epilogue a la recherche du temps perdu. Gynecol. Oncol. 1994, 52(1), 3-9.
38. Makinen, S.; Makela, S.; Weihua, Z.; Warner, M.; Rosenlund, B.; Salmi, S.; Hovatta, O.; Gustafsson, J.K. Localization of oestrogen receptors alpha and beta in human testis. Mol. Hum. Reprod. 2001, 7, 497-503.
39. Torres, M.; Gomez-Pardo, E.; Dressler, G.R.; Gruss, P. Pax-2 controls multiple steps of urogenital development. Development 1995, 121(12), 4057-65.
40. Beekman, J.M.; Allan, G.F.; Tsai, S.Y.; Tsai, M.J.; O'Malley, B.W. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol. Endocrinol. 1993, 7, 1266-74.
41. Belis, J.A.; Adlestein, L.B.; Tarry, W.F. Influence of estradiol on accessory reproductive organs in the castrated male rat. Effects of bromocriptine and flutamide. J. Androl. 1983, 4, 144-9.
42. McKenna, N.J.; Lanz, R.B.; O'Malley, B.W. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 1999, 20, 321-44.
43. Puigserver, P.; Wu, Z.; Park, C.W.; Graves, R.; Wright, M.; Spiegelman, B.M. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998, 92, 829-39.
44. Shang, Y. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat. Rev. Cancer 2006, 6(5), 360-8.
45. McInerney, E.M.; Katzenellenbogen, B.S. Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation. J. Biol. Chem. 1996, 271, 24172-8.
46. Taylor, J.A.; Lewis, K.J.; Lubahn, D.B. Estrogen receptor mutations. Mol. Cell Endocrinol. 1998, 145, 61-6.
47. Cunha, G.R.; Young, P.; Hom, Y.K.; Cooke, P.S.; Taylor, J.A.; Lubahn, D.B. Elucidation of a role for stromal steroid hormone receptors in mammary gland growth and development using tissue recombinants. J. Mammary Gland Biol. Neoplasia. 1997, 2, 393-402.
48. Zwart, W.; de Leeuw, R.; Rondaij, M.; Neefjes, J.; Mancini, M.A.; Michalides, R. The hinge region of the human estrogen receptor determines functional synergy between AF-1 and AF-2 in the quantitative response to estradiol and tamoxifen. J. Cell Sci. 2010, 123(Pt 8), 1253-61.
49. Evans, R.M. The steroid and thyroid hormone receptor superfamily. Science 1988, 240, 889-95.
50. Yang, N.N.; Vanugopalan, M.; Hardikar, S.; Glasebrook, A. Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science 1996, 273, 1222-1225.
51. Harrington, W.R.; Sheng, S.; Barnett, D.H.; Petz, L.N.; Katzenellenbogen, J.A.; Katzenellenbogen, B.S. Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol. Cell Endocrinol. 2003, 206, 13-22.
52. Harris, H.A.; Katzenellenbogen, J.A.; Katzenellenbogen, B.S. Characterization of the biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues in vivo through the use of an ERalpha-selective ligand. Endocrinology 2002, 143, 4172-7.
53. Treuter, E.; Albrektsen, T.; Johansson, L.; Leers, J.; Gustafsson, J.A. A regulatory role for RIP140 in nuclear receptor activation. Mol. Endocrinol. 1998, 12, 864-81.
54. Glaros, S.; Atanaskova, N.; Zhao, C.; Skafar, D.F.; Reddy, K.B. Activation Function-1 Domain of Estrogen Receptor Regulates the Agonistic and Antagonistic Actions of Tamoxifen. Mol. Endocrinol. 2006, 20(5), 996-1008.
55. Drummond, A.E.; Fuller, P.J. The importance of ERb signalling in the ovary. J. Endocrinol. 2010, 205(1), 15-23.
56. Green, S.; Walter, P.; Kumar, V.; Krust, A.; Bornert, J.M.; Argos, P.; Chambon, P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986, 320, 134-9.
57. Palmer, B.D.: Palmer, S.K. Vitellogenin induction by xenobiotic estrogenes in red-eared turtle and African clawed frog. Environ. Health Perspect. 1995, 103(suppl.4), 19-25.
58. King, A.E.; Collins, F.; Klonisch, T.; Sallenave, J.M.; Critchley, H.O.; Saunders, P.T. An additive interaction between the NFkB and estrogen receptor signalling pathways in human endometrial epithelial cells. Hum. Reprod. 2010, 25(2), 510-8.
59. Zhao, C.; Gao, H.; Liu, Y.; Papoutsi, Z.; Jaffrey, S.; Gustafsson, J.A.; Dahlman-Wright, K. Genome-wide mapping of estrogen receptor-beta-binding regions reveals extensive cross-talk with transcription factor activator protein-1. Cancer Res. 2010, 70(12), 5174-83.
60. Batra, S.; Bjellin, L.; Sjogren, C.; Iosif, S.; Widmark, E. Increases in blood flow of the female rabbit urethra following low dose estrogens. J. Urol. 1986, 136, 1360-2.
61. Pike, A.C.; Brzozowski, A.M.; Hubbard, R.E.; Bonn, T.; Thorsell, A.G.; Engstrom, O.; Ljunggren, J.; Gustafsson, J.A.; Carlquist, M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 1999, 18, 4608-18.
62. Zhu, X.; Kwon, C.H.; Schlosshauer, P.W.; Ellenson, L.H.; Baker, S.J. PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. Cancer Res. 2001, 61(11), 4569-75.
63. Warner, M.; Nilsson, S.; Gustafsson, J.A. The estrogen receptor family. Curr. Opin. Obstet. Gynecol. 1999, 11, 249-54.
64. Watts, C.K.; Brady, A.; Sarcevic, B.; deFazio, A.; Musgrove, E.A.; Sutherland, R.L. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclindependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol. Endocrinol. 1995, 9, 1804-13.
65. Björnström, L.; Sjöberg, M. Estrogen receptor-dependent activation of AP-1 via non-genomic signaling. Nucl. Recept. 2004, 14(1), 3.
66. Chapman, J.A.; DiSaia, P.J.; Osann, K.; Roth, P.D.; Gillotte, D.L. Berman ML. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am. J. Obstet. Gynecol. 1996, 175, 1195-200.
67. Eriksson, M.A.; Hard, T.; Nilsson, L. Molecular dynamics simulations of the glucocorticoid receptor DNA-binding domain in complex with DNA and free in solution. Biophys. J. 1995, 68, 402-26.
68. Webb, P.; Lopez, G.N.; Uht, R.M.; Kushner, P.J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol. 1995, 9, 443-56.
69. Webb, P.; Nguyen, P.; Shinsako, J.; Anderson, C.; Feng, W.; Nguyen, M.P.; Chen, D.; Huang, S.M.; Subramanian, S.; McKinerney, E.; Katzenellenbogen, B.S.; Stallcup, M.R.; Kushner, P.J. Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Mol. Endocrinol. 1998, 12, 1605-18.
70. Schmutzler, R.K.; Sanchez, M.; Lehrer, S.; Chaparro, C.A.; Phillips, C.; Rabin, J.; Schachter, B. Incidence of an estrogen receptor polymorphism in breast cancer patients. Breast Cancer Res. Treat. 1991, 19, 111-7.
71. Barakat, R.R. Screening for endometrial cancer in the patient receiving tamoxifen for breast cancer. J. Clin. Oncol. 1999, 17(7), 1967-8.
72. Barkhem, T.; Carlson, B.; Nilsson.; Enmark, E.; Gustafsson, J.-A.; Nilsson, S. Differential response of estrogen receptor α and estrogen receptor β to partial agonists/antagonists. Mol. Pharmacol. 1998, 54, 105-12.
73. Migliaccio, A.; Rotondi, A.; Auricchio, F. Estradiol receptor: phosphorylation on tyrosine in uterus and interaction with antiphosphotyrosine antibody. EMBO J. 1986, 5, 2867-72.
74. Arnold, S.F.; Vorojeikina, D.P.; Notides, A.C. Phosphorylation of tyrosine 537 on the human estrogen receptor is required for binding to an estrogen response element. J. Biol. Chem. 1995, 270, 30205-12.
75. Arnold, S.F.; Obourn, J.D.; Yudt, M.R.; Carter, T.H.; Notides, A.C. In vivo and in vitro phosphorylation of the human estrogen receptor. J. Steroid Biochem. Mol. Biol. 1995, 52, 159-71.
76. Cavailles, V.; Garcia, M.; Rochefort, H. Regulation of cathepsin-D and pS2 gene expression by growth factors in MCF7 human breast cancer cells. Mol. Endocrinol. 1989, 3, 552-8.
77. Dovrat, S.; Figer, A.; Fidder, H.H.; Neophytou, P.; Fireman, Z.; Geva, R.; Zidan, J.; Flex, D.; Meir, S.B.; Friedman, E. Mutational analysis of hMsh6 in Israeli HNPCC and HNPCC-like families. Fam. Cancer 2005, 4(4), 291-4.
78. Arnold, S.F.; Obourn, J.D.; Jaffe, H.; Notides, A.C. Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol. Endocrinol. 1994, 8, 1208-14.
79. Arnold, S.F.; Obourn, J.D.; Jaffe, H.; Notides, A.C. Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by src family tyrosine kinases in vitro. Mol. Endocrinol. 1995, 9, 24-33.
80. Katzenellenbogen, B.S.; Montano, M.M.; Ediger, T.R.; Sun, J.; Ekena, K.; Lazennec, G.; Martini, P.G.; McInerney, E.M.; Delage-Mourroux, R.; Weis, K.; Katzenellenbogen, J.A. Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog. Horm. Res. 2000, 55, 163-93.
81. Astroff, B.; Eldridge, B.; Safe, S. Inhibition of the 17 betaestradiol-induced and constitutive expression of the cellular protooncogene c-fos by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the female rat uterus. Toxicol. Lett. 1991, 56, 305-15.
82. Caira, F.; Antonson, P.; Pelto-Huikko, M.; Treuter, E.; Gustafsson, J.A. Cloning and characterization of RAP250, a novel nuclear receptor coactivator. J. Biol. Chem. 2000, 275, 5308-17.
83. Palmieri, C.; Cheng, G.J.; Saji, S.; Zelada-Hedman, M.; Warri, A.; Weihua, Z.; Van Noorden, S.; Wahlstrom, T.; Coombes, R.C.; Warner, M.; Gustafsson, J.A. Estrogen receptor beta in breast cancer. Endocr. Relat. Cancer 2002, 9, 1-13.
84. Chen, D.; Ma, H.; Hong, H.; Koh, S.S.; Huang, S.M.; Schurter, B.T.; Aswad, D.W.; Stallcup, M.R. Regulation of transcription by a protein methyltransferase. Science 1999, 284, 2174-7.
85. Jiang, J.; Sarwar, N.; Peston, D.; Kulinskaya, E.; Shousha, S.; Coombes, R.C.; Ali, S. Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients. Clin. Cancer Res. 2007, 13(19), 5769-76.
86. Nagamani, M.; Hannigan, E.V.; Dinh, T.V.; Stuart, C.A. Hyperinsulinemia and stromal luteinization of the ovaries in postmenopausal women with endometrial cancer. J. Clin. Endocrinol. Metab. 1988, 67(1), 144-8.
87. Paige, L.A.; Christensen, D.J.; Gron, H.; Norris, J.D.; Gottlin, E.B.; Padilla, K.M.; Chang, C.Y.; Ballas, L.M.; Hamilton, P.T.; McDonnell, D.P.; Fowlkes, D.M. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc. Natl. Acad. Sci. USA 1999, 96, 3999-4004.
88. Ma, H.; Hong, H.; Huang, S.M.; Irvine, R.A.; Webb, P.; Kushner, P.J.; Coetzee, G.A.; Stallcup, M.R. Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol. Cell Biol. 1999, 19, 6164-73.
89. Sun, M.; Paciga, J.E.; Feldman, R.I.; Yuan, Z.; Coppola, D.; Lu, Y.Y.; Shelley, S.A.; Nicosia, S.V.; Cheng, J.Q. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor α (ERα) via interaction between ERα and PI3K. Cancer Res. 2001, 61(16), 5985-91.
90. Ma, Y.; Hu, C.; Riegel, A.T.; Fan, S.; Rosen, E.M. Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-α activity. Mol. Endocrinol. 2007, 21(8), 1905-23.
91. erbB2. Science 1992, 256, 1205-1210.
92. Poland, A.; Knutson, J.C. 2,3,7,8-tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. Annu. Rev. Pharmacol. Toxicol. 1982, 22, 517-54.
93. Skrzypczak, M.; Szymczak, S.; Kaczmarek, L.; Jakowicki, J.A. Estrogen receptor alpha (ER-α) and beta (ER-β) mRNAs in normal endometrium, endometrial adenocarcinoma: Down-regulation of ER-β in neoplastic tissues. Europ. J. Obstet. Gynecol. Reprod. Biol. A. 1999, 86, S9.
94. Catalano, S.; Mauro, L.; Marsico, S.; Giordano, C.; Rizza, P.; Rago, V.; Montanaro, D.; Maggiolini, M.; Panno, M.L.; Andó, S.Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor α in MCF-7 cells. J. Biol. Chem. 2004, 279(19), 19908-15.
95. Speirs, V.; Kerin, M.J.; Walton, D.S.; Newton, C.J.; Desai, S.B.; Atkin, S.L. Direct activation of oestrogen receptor-α by interleukin-6 in primary cultures of breast cancer epithelial cells. Br. J. Cancer 2000, 82(7), 1312-1316.
96. Aronica, S.M.; Katzenellenbogen, B.S. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol. Endocrinol. 1993, 7, 743-52.
97. Giguere, V. Orphan nuclear receptors: from gene to function. Endocrynol. Rev. 1999, 20, 689-725.
98. Vega, R.B.; Kelly, D.P. A role for estrogen-related receptor alpha in the control of mitochondrial fatty acid beta-oxidation during brown adipocyte differentiation. J. Biol. Chem. 1997, 272, 31693-9.
99. Weigel, N.L.; Zhang, Y. Ligand-independent activation of steroid hormone receptors. J. Mol. Med. 1998, 76, 469-79.
100. Nagamani, M.; Doherty, M.G.; Smith, E.R.; Chandrasekhar, Y. Increased bioactive luteinizing hormone levels in postmenopausal women with endometrial cancer. Am. J. Obstet. Gynecol. 1992, 167(6), 1825-30.
101. Poola, I.; Abraham, J.; Baldwin, K. Identification of ten exon deleted ERbeta mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of estrogen receptor beta mRNA is distinct from that of estrogen receptor alpha. FEBS Lett. 2002, 516, 133-8.
102. Tong, D.; Schuster, E.; Seifert, M.; Czerwenka, K.; Leodolte, S.; Zeillinger, R. Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines. Breast Cancer Res. Treat. 2002, 71, 249-255.
103. Zou, A.; Marschkem, K.B.; Arnold, K.E.; Berger, E.M.; Fitzgerald, P.; Mais, D.E.; Allegretto, E.A. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen. Mol. Endocrinol. 1999, 13, 418-30.
104. Rey, J.M.; Pujol, P.; Dechaud, H.; Edouard, E.; Hedon, B.; Maudelonde, T. Expression of oestrogen receptor-α splicing variants and oestrogen receptor-β in endometrium of infertile patients. Mol. Hum. Reprod. 1998, 4, 641-7.
105. Lannigan, D.A, Estrogen receptor phosphorylation. Steroids 2003, 68(1), 1-9.
106. Arnold, S.F.; Obourn, J.D.; Jaffe, H.; Notides, A.C. Phosphorylation of the human estrogen receptor by mitogen-activated protein kinase and casein kinase II: consequence on DNA binding. J. Steroid. Biochem. Mol. Biol. 1995, 55, 163-72.
107. Migliaccio, A.; Di Domenico, M.; Green, S.; de Falco, A.; Kajtaniak, E.L.; Blasi, F.; Chambon, P.; Auricchio, F. Phosphorylation on tyrosine of in vitro synthesized human estrogen receptor activates its hormone binding. Mol. Endocrinol. 1989, 3, 1061-9.
108. Chen, I.; McDougal, A.; Wang, F.; Safe, S. Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis 1998, 19, 1631-9.
109. Esteller, M.; Levine, R.; Baylin, S.B.; Ellenson, L.H.; Herman, J.G. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998, 17(18), 2413-7.
110. Tchoudakova, A.; Pathak, S.; Callard, G.V. Molecular cloning of an estrogen receptor beta subtype from the goldfish, Carassius auratus. Gen. Comp. Endocrinol. 1999, 113, 388-400.
111. Tremblay, A.; Tremblay, G.B.; Labrie, F.; Giguère, V. Ligandindependent recruitment of SRC-1 to estrogen receptor β through phosphorylation of activation function AF-1. Mol. Cell 1999, 3(4), 513-9.
112. [Tremblay, A.; Giguère, V. Contribution of steroid receptor coactivator-1 and CREB binding protein in ligand-independent activity of estrogen receptor β. J. Steroid Biochem. Mol. Biol. 2001, 77(1), 19-27.
113. Vivar, O.I.; Saunier, E.F.; Leitman, D.C.; Firestone, G.L.; Bjeldanes, L.F. Selective activation of estrogen receptor-β target genes by 3,3′-diindolylmethane. Endocrinology 2010, 151(4), 1662-7.
114. Spink, D.C.; Eugster, H.P.; Lincoln, D.W.; Schuetz, J.D.; Schuetz, E.G.; Johnson, J.A.; Kaminsky, L.S.; Gierthy, J.F. 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1A1: a comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-pdioxin in MCF-7 cells with those from heterologous expression of the cDNA. Arch. Biochem. Biophys. 1992, 293, 342-8.
115. Spink, D.C.; Hayes, C.L.; Young, N.R.; Christou, M.; Sutter, T.R.; Jefcoate, C.R.; Gierthy, J.F. The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on estrogen metabolism in MCF-7 breast cancer cells: evidence for induction of a novel 17 betaestradiol 4-hydroxylase. J. Steroid Biochem. Mol. Biol. 1994, 51, 251-8.
116. Chu, S.; Fuller, P.J. Identification of a splice variant of the rat estrogen receptor beta gene. Mol. Cell Endocrinol. 1997, 132, 195-9.
117. Hall, J.M.; McDonnell, D.P. The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999, 140, 5566-78.
118. Fuqua, S.A.; Chamness, G.C.; McGuire, W.L. Estrogen receptor mutations in breast cancer. J. Cell Biochem. 1993, 51, 135-9.
119. McMahon, C.; Suthiphongchai, T.; DiRenzo, J.; Ewen, M.E. P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc. Natl. Acad. Sci. USA 1999, 96, 5382-7.
120. Witek, A.; Skalba, P.; Paul, M.; Graniczka, M.; Mazurek, U.; Chromy, G.; Wilczok, T. Evaluation of wild-type estrogen receptor beta and its isoforms: ER-beta/delta 5/6 i ER-beta/delta 6 in endometrial adenocarcinoma. Ginekol. Pol. 2003, 74(9), 897-902.
121. Wu, H.; Chen, Y.; Liang, J.; Shi, B.; Wu, G.; Zhang, Y.; Wang, D.; Li, R.; Yi, X.; Zhang, H.; Sun, L.; Shang, Y. Hypomethylationlinked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 2005, 438(7070), 981-7.
122. Bunone, G.; Briand, P.A.; Miksicek, R.J.; Picard, D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996, 15, 2174-83.
123. Petersen, D.N.; Tkalcevic, G.T.; Koza-Taylor, P.H.; Turi, T.G.; Brown, T.A. Identification of estrogen receptor beta2, a functional variant of estrogen receptor beta expressed in normal rat tissues. Endocrinology 1998, 139, 1082-92.
124. Seol, W.; Chung, M.; Moore, D.D. Novel receptor interaction and repression domains in the orphan receptor SHP. Mol. Cell Biol. 1997, 17, 7126-31.
125. Scoggin, K.E.; Ulloa, A.; Nyborg, J.K, The oncoprotein Tax binds the SRC-1-interacting domain of CBP/p300 to mediate transcriptional activation. Mol. Cell Biol. 2001, 21(16), 5520-30.
126. Stambolic, V.; Tsao, M.S.; MacPherson, D.; Suzuki, A.; Chapman, W.B.; Mak, T.W. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/-mice. Cancer Res. 2000, 60(13), 3605-11.
127. Luo, J.; Sladek, R.; Bader, J.A.; Matthyssen, A.; Rossant, J.; Giguere, V. Placental abnormalities in mouse embryos lacking the orphan nuclear receptor ERR-beta. Nature 1997, 388, 778-82.
128. Waters, K.M.; Rickard, D.J.; Riggs, B.L.; Khosla, S.; Katzenellenbogen, J.A.; Katzenellenbogen, B.S.; Moore, J.; Spelsberg, T.C. Estrogen regulation of human osteoblast function is determined by the stage of differentiation and the estrogen receptor isoform. J. Cell Biochem. 2001, 83, 448-62.
129. Benecke, A.; Chambon, P.; Gronemeyer, H. Synergy between estrogen receptor alpha activation functions AF1 and AF2 mediated by transcription intermediary factor TIF2. EMBO Rep. 2000, 1(2), 151-7.
130. Chen, H.; Lin, R.J.; Xie, W.; Wilpitz, D.; Evans, R.M. Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell 1999, 98, 675-86.
131. Chi, N.; Epstein, J.A. Getting your Pax straight: Pax proteins in development and disease. Trends Genet. 2002, 18(1), 41-7.
132. Dudek, P.; Picard, D. Genomics of signaling crosstalk of estrogen receptor alpha in breast cancer cells. PLoS One 2008, 3(3), e1859.
133. Hard, T.; Kellenbach, E.; Boelens, R.; Dahlman, K.; Carlstedt-Duke, J.; Freedman, L.P.; Maler, B.A.; Hyde, E.I.; Kaptein, R. 1H NMR studies of the glucocorticoid receptor DNA-binding domain: sequential assignments and dentification of secondary structure elements. Biochemistry 1990, 29, 9015-23.
134. Quenby, S.M.; Gazvani, M.R.; Brazeau, C.; Neilson, J.; Lewis-Jones, D.I.; Vince, G. Oncogenes and tumour suppressor genes in first trimester human fetal gonadal development. Mol. Hum. Reprod. 1999, 5, 737-41.
135. Nettles, K.W.; Sun, J.; Radek, J.T.; Sheng, S.; Rodriguez, A.L.; Katzenellenbogen, J.A.; Katzenellenbogen, B.S.; Greene, G.L. Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptors. Mol. Cell 2004, 13, 317-27.
136. Porter, W.; Saville, B.; Hoivik, D.; Safe, S. Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol. Endocrinol. 1997, 11, 1569-80.
137. Porter, W.; Wang, F.; Wang, W.; Duan, R.; Safe, S. Role of estrogen receptor/Sp1 complexes in estrogen-induced heat shock protein 27 gene expression. Mol. Endocrinol. 1996, 10, 1371-8.
138. Girault, I.; Bièche, I.; Lidereau, R. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer. Maturitas 2006, 54(4), 342-51.
139. Cariou, S; Donovan, J.C.; Flanagan, W.M.; Milic, A.; Bhattacharya, N.; Slingerland, J.M. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc. Natl. Acad. Sci. USA 2000, 97, 9042-6.
140. Tibbetts, T.A.; Conneely, O.M.; O'Malley, B.W. Progesterone via its receptor antagonizes the pro-inflammatory activity of estrogen in the mouse uterus. Biol. Reprod. 1999, 60, 1158-65.
141. Todo, T.; Adachi, S.; Yamauchi, K. Molecular cloning and characterization of Japanese eel estrogen receptor cDNA. Mol. Cell Endocrinol. 1996, 119, 37-45.
142. Montano, M.M.; Ekena, K.; Delage-Mourroux, R.; Chang, W.; Martini, P.; Katzenellenbogen, B.S. An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc. Natl. Acad. Sci. USA 1999, 96, 6947-52.
143. Neubauer, B.; Blume, C.; Cricco, R.; Greiner, J.; Mawhinney, M. Comparative effects and mechanisms of castration, estrogen antiandrogen, and anti-estrogen-induced regression of accessory sex organ epithelium and muscle. Invest. Urol. 1981, 18, 229-34.
144. Sutherland, R.; Green, M.D.; Hall, R.E.; Reddel, R.R.; Taylor, I.W. Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur. J. Cancer Clin. Oncol. 1983, 19, 615-21.
145. Schlosshauer, P.W.; Pirog, E.C.; Levine, R.L.; Ellenson, L.H. Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma. Mod. Pathol. 2000, 13(10), 1066-71.
146. Onate, S.A.; Boonyaratanakornkit, V.; Spencer, T.E.; Tsai, S.Y.; Tsai, M.J.; Edwards, D.P.; O'Malley, B.W. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J. Biol. Chem. 1998, 273, 12101-8.
147. Arai, Y. Nature of metaplasia in rat coagulating glands induced by neonatal treatment with estrogen. Endocrinology 1970, 86, 918-20.
148. Zhou, G.; Cummings, R.; Li, Y.; Mitra, S.; Wilkinson, H.A.; Elbrecht, A.; Hermes, J.D.; Schaeffer, J.M.; Smith, R.G.; Moller, D.E. Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer. Mol. Endocrinol. 1998, 12, 1594-604.
149. Sharpe, R.M.; Atanassova, N.; McKinnell, C.; Parte, P.; Turner, K.J.; Fisher, J.S.; Kerr, J.B.; Groome, N.P.; MacPherson, S.; Millar, M.R.; Saunders, P.T. Abnormalities in functional development of the Sertoli cells in rats treated neonatally with diethylstilbestrol: a possible role for estrogens in Sertoli cell development. Biol. Reprod. 1998, 59, 1084-94.
150. Foley, E.F.; Jazaeri, A.A.; Shupnik, M.A.; Jazaeri, O.; Rice, L.W. Selective loss of estrogen receptor β in malignant human colon. Cancer Res. 2000, 60, 245-8.
151. Li, Y.; Li, Y.; Zhang, T.; Chan, W.K. The aryl hydrocarbon receptor nuclear translocator-interacting protein 2 suppresses the estrogen receptor signaling via an Arnt-dependent mechanism. Arch. Biochem. Biophys. 2010, 502(2), 121-129.
152. Darimont, B.D.; Wagner, R.L.; Apriletti, J.W.; Stallcup, M.R.; Kushner, P.J.; Baxter, J.D.; Fletterick, R.J.; Yamamoto, K.R. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev. 1998, 12, 3343-56.
153. Schecter, A.; Birnbaum, L.; Ryan, J.J.; Constable, J.D. Dioxins: an overview. Environ. Res. 2006, 101 (3), 419-28.
154. Poland, A.; Knutson, J.C. 2,3,7,8-tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. Ann. Rev. Pharmacol. Toxicol. 1982, 22, 517-554.
155. Bjeldanes, L.F.; Kim, J.Y.; Grose, K.R.; Bartholomew, J.C.; Bradfield, C.A. Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinole in vitro and in vivo: Comparison with 2,3,7,8- tetrachlorodibenzo-p-dioxine. Proc. Natl. Acad. Sci. USA 1991, 88, 9543-9547.
156. Rushmore, T.H.; Kong, A.N.T. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr. Drug Metabol. 2002, 3, 481-490.
157. Rubinfeld, B.; Albert, I.; Porfiri, E.; Fiol, C.; Munemitsu, S.; Polakis, P. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 1996, 272(5264), 1023-6.
158. Brandenberger, A.W.; Tee, M.K.; Lee, J.Y.; Chao, V.; Jaffe, R.B. Tissue distribution of estrogen receptors alpha (ER-alpha) and beta (ER-beta) mRNA in the midgestational human fetus. J. Clin. Endocrinol. Metab. 1997, 82, 3509-12.
159. Atanassova, N.; McKinnell, C.; Walker, M.; Turner, K.J.; Fisher, J.S.; Morley, M.; Millar, M.R.; Groome, N.P.; Sharpe, R.M. Permanent effects of neonatal estrogen exposure in rats on reproductive hormone levels, Sertoli cell number, and the efficiency of spermatogenesis in adulthood. Endocrinology 1999, 140, 5364-73.
160. Auricchio, F.; Migliaccio, A.; Castoria, G.; Rotondi, A.; Di Domenico, M.; Pagano, M.; Nola, E. Phosphorylation on tyrosine of oestradiol-17 beta receptor in uterus and interaction of oestradiol-17 beta and glucocorticoid receptors with antiphosphotyrosine antibodies. J. Steroid Biochem. 1987, 27, 45-53.
161. Rickard, D.J.; Waters, K.M.; Ruesink, T.J.; Khosla, S.; Katzenellenbogen, J.A.; Katzenellenbogen, B.S.; Riggs, B.L.; Spelsberg, T.C. Estrogen receptor isoform-specific induction of progesterone receptors in human osteoblasts. J. Bone Miner. Res. 2002, 17, 580-92.
162. Bertazzi, P.A. Long-term effects of chemical disasters. Lessons and results from Seveso. Sci. Total. Environ. 1991, 106, 5-20.
163. Bibbo, M.; Gill, W.B.; Azizi, F.; Blough, R.; Fang, V.S.; Rosenfield, R.L.; Schumacher, G.F.; Sleeper, K.; Sonek, M.G.; Wied, G.L. Follow-up study of male and female offspring of DESexposed mothers. Obstet. Gynecol. 1977, 49, 1-8.
164. Xu, J.; Qiu, Y.; DeMayo, F.J.; Tsai, S.Y.; Tsai, M.J.; O'Malley, B.W. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 1998, 279, 1922-5.
165. Lu, B.; Leygue, E.; Dotzlaw, H.; Murphy, L.J.; Murphy, L.C.; Watson, P.H. Estrogen receptor-β mRNA variants in human and murine tissues. Mol. Cell Endocrinol. 1998, 138, 99-203.
166. El-Ashry, D.; Miller, D.L.; Kharbanda, S.; Lippman, M.E.; Kern, F.G. Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 1997, 15, 423-35.
167. El-Tanani, M.K.; Green, C.D. Two separate mechanisms for ligand-independent activation of the estrogen receptor. Mol. Endocrinol. 1997, 11, 928-37.
168. Poland, A.; Glover, E.; Kende, A.S. Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. J. Biol. Chem. 1976, 251, 4936-46.
169. Gee, A.C.; Carlson, K.E.; Martini, P.G.; Katzenellenbogen, B.S.; Katzenellenbogen, J.A. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. Mol, Endocrinol. 1999, 13, 1912-23.
170. Hayashi S.; Sakamoto, T.; Inoue, A.; Yoshida, N.; Omoto, Y.; Yamaguchi, Y. Estrogen and growth factor signaling pathway: basic approaches for clinical application. J. Steroid. Biochem. Mol. Biol. 2003, 86, 433-4.
171. Bodine, P.V.; Henderson, R.A.; Green, J.; Aronow, M.; Owen, T.; Stein, G.S.; Lian, J.B.; Komm, B.S. Estrogen receptor-alpha is developmentally regulated during osteoblast differentiation and contributes to selective responsiveness of gene expression. Endocrinology 1998, 139, 2048-57.
172. Goodman, M.T.; Hankin, J.H.; Wilkens, L.; Lyu, L.C.; McDuffie, K.; Liu, L.Q.; Kolonel, L.N. Diet, body size, physical activity, and the risk of endometrial cancer. Cancer Res. 1997, 22, 5077-85.
173. Weigel, N.L. Steroid hormone receptors and their regulation by phosphorylation. Biochem. J. 1996, 319, 657-67.
174. Hecht, J.L.; Mutter, G.L. Molecular and pathologic aspects of endometrial carcinogenesis. J. Clin. Oncol. 2006, 24(29), 4783-91.
175. Smith, C.L.; Conneely, O.M.; O'Malley, B.W. Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. Proc. Natl. Acad. Sci. USA 1993, 90, 6120-4.
176. Smith, C.L.; Nawaz, Z.; O'Malley, B.W. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol. 1997, 11, 657-66.
177. Wolffe, A.P.; Hayes, J.J. Chromatin disruption and modification. Nucleic Acids Res. 1999, 27, 711-20.
178. Xu, L.; Glass, C.K.; Rosenfeld, M.G. Coactivator and corepressor complexes in nuclear receptor function. Curr. Opin. Genet. Dev. 1999, 9, 140-7.
179. Tan, N.S.; Lam, T.J.; Ding, J.L. The first contiguous estrogen receptor gene from a fish, Oreochromis aureus: evidence for multiple transcripts. Mol. Cell Endocrinol. 1996, 120, 177-92.
180. Vazquez, F.; Rodriguez-Manzaneque, J.C.; Lydon, J.P.; Edwards, D.P.; O'Malley, B.W.; Iruela-Arispe, M.L. Progesterone regulates proliferation of endothelial cells. J. Biol. Chem. 1999, 274, 2185-92.
181. Suen, C.S.; Berrodin, T.J.; Mastroeni, R.; Cheskis, B.J.; Lyttle, C.R.; Frail, D.E. A transcriptional coactivator, steroid receptor coactivator-3, selectively augments steroid receptor transcriptional activity. J. Biol. Chem. 1998, 273, 27645-53.
182. Chamness, G.C.; McGuire, W.L. Estrogen receptor in the rat uterus. Physiological forms and artifacts. Biochemistry 1972, 11, 2466-72.
183. Nagamani, M.; Stuart, C.A.; Doherty, M.G. Increased steroid production by the ovarian stromal tissue of postmenopausal women with endometrial cancer. J. Clin. Endocrinol. Metab. 1992, 74(1), 172-6.
184. Rosenfeld, C.S.; Ganjam, V.K.; Taylor, J.A.; Yuan, X.; Stiehr, J.R.; Hardy, M.P.; Lubahn, D.B. Transcription and translation of estrogen receptor-beta in the male reproductive tract of estrogen receptor-alpha knock-out and wild-type mice. Endocrinology 1998, 139, 2982-7.
185. Jazaeri, A.A.; Nunes, K.J.; Dalton, M.S.; Xu, M.; Shupnik, M.A.; Rice, L.W. Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene 2001, 20, 6965-9.
186. Chen, Z.; Katzenellenbogen, B.S.; Katzenellenbogen, J.A.; Zhao, H. Directed evolution of human estrogen receptor variants with significantly enhanced androgen specificity and affinity. J. Biol. Chem. 2004, 279(32), 33855-64.
187. Feng, W.; Ribeiro, R.C.; Wagner, R.L.; Nguyen, H.; Apriletti, J.W.; Fletterick, R.J.; Baxter, J.D.; Kushner, P.J.; West, B.L. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 1998, 280, 1747-9.
188. Dufour, C.R.; Wilson, B.J.; Huss, J.M.; Kelly, D.P.; Alaynick, W.A.; Downes, M.; Evans, R.M.; Blanchette, M.; Giguère, V. Genome-wide orchestration of cardiac functions by the orphan nuclear receptors ERRalpha and gamma. Cell Metab. 2007, 5(5), 345-56.
189. Peiffer, S.L.; Herzog, T.J.; Tribune, D.J.; Mutch, D.G.; Gersell, D.J.; Goodfellow, P.J. Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. Cancer Res. 1995, 55(9), 1922-6.
190. Luconi, M.; Muratori, M.; Forti, G.; Baldi, E. Identification and characterization of a novel functional estrogen receptor on human sperm membrane that interferes with progesterone effects. J. Clin. Endocrinol. Metab. 1999, 84, 1670-8.
191. Bombail, V.; Collins, F.; Brown, P.; Saunders, P.T. Modulation of ERα transcriptional activity by the orphan nuclear receptor ERRβ and evidence for differential effects of long- and short-form splice variants. Mol. Cell Endocrinol. 2010, 314(1), 53-61.
192. Shao, D.; Lazar, M.A. Modulating nuclear receptor function: may the phos be with you. J. Clin. Invest. 1999, 103, 1617-8.
193. Villena, J.A.; Hock, M.B.; Chang, W.Y.; Barcas, J.E.; Giguère, V.; Kralli, A. Orphan nuclear receptor estrogen-related receptor alpha is essential for adaptive thermogenesis. Proc. Natl. Acad. Sci. USA 2007, 104(4), 1418-23.
194. Huss, J.M.; Imahashi, K.; Dufour, C.R.; Weinheimer, C.J.; Courtois, M.; Kovacs, A.; Giguère, V.; Murphy, E.; Kelly, D.P. The nuclear receptor ERRalpha is required for the bioenergetic and functional adaptation to cardiac pressure overload. Cell Metab. 2007, 6(1), 25-37.
195. Luo, J.; Sladek, R.; Carrier, J.; Bader, J.A.; Richard, D.; Giguère, V. Reduced fat mass in mice lacking orphan nuclear receptor estrogen-related receptor alpha. Mol. Cell Biol. 2003, 23(22), 7947-56.
196. Bonnelye, E.; Vanacker, J.M.; Spruyt, N.; Alric, S.; Fournier, B.; Desbiens, X.; Laudet, V. Expression of the estrogen-related receptor 1 (ERR-1) orphan receptor during mouse development. Mech. Dev. 1997, 65, 71-85.
197. Bozdogan, O.; Atasoy, P.; Erekul, S.; Bozdogan, N.; Bayram, M. Apoptosis-related proteins and steroid hormone receptors in normal, hyperplastic and neoplastic endometrium. Int. J. Gynecol. Pathol. 2002, 21, 375-82.
198. Alaynick, W.A.; Kondo, R.P.; Xie, W.; He, W.; Dufour, C.R.; Downes, M.; Jonker, J.W.; Giles, W.; Naviaux, R.K.; Giguère, V.; Evans, R.M. ERRgamma directs and maintains the transition to oxidative metabolism in the postnatal heart. Cell Metab. 2007, 6(1), 13-24.
199. Tsai, C.C.; Kao, H.Y.; Yao, T.P; McKeown, M.; Evans, R.M. SMRTER, a Drosophila nuclear receptor coregulator, reveals that EcR-mediated repression is critical for development. Mol. Cell. 1999, 4, 5-86.
200. Tsai, M.J.; O'Malley, B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 1994, 63, 451-86.
201. Patrone, C.; Gianazza, E.; Santagati, S.; Agrati, P.; Maggi, A. Divergent pathways regulate ligand-independent activation of ER alpha in SK-N-BE neuroblastoma and COS-1 renal carcinoma cells. Mol. Endocrinol. 1998, 12, 835-41.
202. Poola, I.; Fuqua, S.A.; De Witty, R.L.; Abraham, J.; Marshallack, J.J.; Liu, A. Estrogen receptor alpha-negative breast cancer tissues express significant levels of estrogen-independent transcription factors, ERbeta1 and ERbeta5: potential molecular targets for chemoprevention. Clin. Cancer Res. 2005, 11(20), 7579-85.
203. Troisi, R.; Potischman, N.; Hoover, R.N.; Siiteri, P.; Brinton, L.A. Insulin and endometrial cancer. Am. J. Epidemiol. 1997, 146(6), 476-82.
204. Sillero-Arenas, M.; Delgado-Rodriguez, M.; Rodigues-Canteras, R.; Bueno-Cavanillas, A.; Galvez-Vargas, R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet. Gynecol. 1992, 79, 286-94.
205. Trowbridge, J.M.; Rogatsky, I.; Garabedian, M.J. Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proc. Natl. Acad. Sci. USA 1997, 94, 10132-7.
206. Vanacker, J.M.; Bonnelye, E.; Delmarre, C.; Laudet, V. Activation of the thyroid hormone receptor alpha gene promoter by the orphan nuclear receptor ERR alpha. Oncogene 1998, 17, 2429-35.
207. Wurtz, J.M.; Bourguet, W.; Renaud, J.P.; Vivat, V.; Chambon, P.; Moras, D.; Gronemeyer, H. A canonical structure for the ligandbinding domain of nuclear receptors. Nat. Struct. Biol. 1996, 3, 206.
208. Wilcox, A.J.; Baird, D.D.; Weinberg, C.R.; Hornsby, P.P.; Herbst, A.L. Fertility in men exposed prenatally to diethylstilbestrol. N. Engl. J. Med. 1995, 332, 1411-6.
209. Zhu, Y.; Qi, C.; Jain, S.; Le Beau, M.M.; Espinosa, R.; Atkins, G.B.; Lazar, M.A.; Yeldandi, A.V.; Rao, M.S.; Reddy, J.K. Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer. Proc. Natl. Acad. Sci. USA 1999, 96, 10848-53.
210. Ludes-Meyers, J.H.; Liu, Y.M.; Munoz-Medellin, D.; Hilsenbeck, S.G.; Brown, P.H. AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene 2001, 20, 2771-2780.
211. Tsuchida, K.; Chaki, H.; Takakura, T.; Kotsubo, H.; Tanaka, T.; Aikawa, Y.; Shiozawa, S.; Hirono, S. Discovery of nonpeptidic small-molecule AP-1 inhibitors: lead hopping based on a threedimensional pharmacophore model. J. Med. Chem. 2006, 49(1), 80-91.
212. Pande, V.; Ramos, M.J.; Gago, F. The Protein Kinase inhibitor Balanol: structure-activity relationship and structure-based computational studies. Anti-Cancer Agents Med. Chem. 2008, 8 (6), 638-645.
213. Favata, M.F.; Horiuchi, K.Y.; Manos, E.J.; Daulerio, A.J.; Stradley, D.A.; Feeser, W.S.; Van Dyk, D.E.; Pitts, W.J.; Earl, R.A.; Hobbs, F.; Copeland, R.A.; Magolda, R.L.; Scherle, P.A.; Trzaskos, J.M. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 1998, 273(29), 18623-32.
214. Steinberg, R.; Harari, O.A.; Lidington, E.A.; Boyle, J.J.; Nohadani, M.; Samarel, A.M.; Ohba, M.; Haskard, D.O.; Mason, J.C. A protein kinase Cepsilon-anti-apoptotic kinase signaling complex protects human vascular endothelial cells against apoptosis through induction of Bcl-2. J. Biol. Chem. 2007, 282(44), 32288-97.
215. Alessi, D.R.; Cuenda, A.; Cohen, P.; Dudley, D.T.; Saltiel, A.R. PD 098059 is a specific inhibitor of the activation of mitogenactivated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 1995, 270(46), 27489-94.
216. Jhabvala-Romero, F.; Evans, A.; Guo, S.H.; Denton, M.; Clinton, G.M. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2. Oncogene 2003, 22, 8178-8186.
217. Malumbres, M.; Barbacid, M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci. 2005, 30, 630-641.
218. Borgne, A.; Versteege, I.; Mahé, M.; Studeny, A.; Léonce, S.; Rodriguez, M.; Hickman, J.A.; Meijer, L.; Golsteyn, R.M. Analysis of cyclin B1 in apoptosis and mitotic catastrophe induced by camptothecin treatment in HT29 cells. Oncogene 2006, 25, 7361-7372.
219. Guzi, T. Cyc-202 Cyclacel. Curr. Opinion Investig. Drugs 2004, 5, 1311-1318.
220. Squires, M.S.; Cooke, L.; Lock, V.; Qi, W.; Lewis, E.J.; Thompson, N.T.; Lyons, J.F.; Mahadevan, D. AT7519, a cyclindependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol. Cancer Ther. 2010, 9(4), 920-928.
221. Byth, K.F.; Thomas, A.; Hughes, G.; Forder, C.; McGregor, A.; Geh, C.; Oakes, S.; Green, C.; Walker, M.; Newcombe, N.; Green, S.; Growcott, J.; Barker, A.; Wilkinson, R.W. AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts. Mol. Cancer Ther. 2009, 8(7), 1856-66.
222. Ali S, Heathcote DA, Kroll SH, Jogalekar AS, Scheiper B, Patel H, Brackow J, Siwicka A, Fuchter MJ, Periyasamy M, Tolhurst RS, Kanneganti SK, Snyder JP, Liotta DC, Aboagye EO, Barrett AG, Coombes RC. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. Cancer Res. 2009, 69(15), 6208-15
223. Smith, M.E.; Cimica, V.; Chinni, S.; Challagulla, K.; Mani, S.; Kalpana, G.V. Rhabdoid tumor growth is inhibited by Flavopiridol. Clin. Cancer Res. 2008, 14, 523-532.
224. Menu, E.; Garcia, J.; Huang, X.; Di Liberto, M.; Toogood, P.L.; Chen, I.; Vanderkerken, K.; Chen-Kiang, S. A novel therapeutic combination using PD 0332991 and Bortezomib: study in the 5T33MM myeloma model. Cancer Res. 2008, 68(14), 5519-5523.
225. Brasca, M.G.; Albanese, C.; Alzani, R.; Amici, R.; Avanzi, N.; Ballinari, D.; Bischoff, J.; Borghi, D.; Casale, E.; Croci, V.; Fiorentini, F.; Isacchi, A.; Mercurio, C.; Nesi, M.; Orsini, P.; Pastori, W.; Pesenti, E.; Pevarello, P.; Roussel, P.; Varasi, M.; Volpi, D.; Vulpetti, A.; Ciomei, M. Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing. Bioorg. Med. Chem. 2010, 18(5), 1844-53.
226. DePinto, W.; Chu, X.-J.; Yin, X.F.; Smith, M.; Packman, K.; Goelzer, P.; Lovey, A.; Chen, Y.; Qian, H.; Hamid, R.; Xiang, Q.; Tovar, C.; Blain, R.; Nevins, T.; Higgins, B.; Luistro, L.; Kolinsky, K.; Felix, B.; Hussain, S.; Heimbrook, D. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol. Cancer Ther. 2006, 5, 2644-2658.
227. Misra, R.N.; Xiao, H.Y.; Kim, K.S.; Lu, S.; Han, W.C.; Barbosa, S.A.; Hunt, J.T.; Rawlins, D.B.; Shan, W.; Ahmed, S.Z.; Qian, L.; Chen, B.C.; Zhao, R.; Bednarz, M.S.; Kellar, K.A.; Mulheron, J.G.; Batorsky, R.; Roongta, U.; Kamath, A.; Marathe, P.; Ranadive, S.A.; Sack, J.S.; Tokarski, J.S.; Pavletich, N.P.; Lee, F.Y.; Webster, K.R.; Kimball, S.D. N-(cycloalkylamino)acyl-2- aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1- dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J. Med. Chem. 2004, 47(7), 1719-28.
228. Fabian, M.A.; Biggs III, W.H.; Treiber, D.K.; Atteridge, C.T.; Azimioara, M.D.; Benedetti, M.G.; Carter, T.A.; Ciceri, P.; Edeen, P.T.; Floyd, M.; Ford, J.M.; Galvin, M.; Gerlach, J.L.; Grotzfeld, R.M.; Herrgard, S.; Insko, D.E.; Insko, M.A.; Lai, A.G.; Lelias, J.-M.; Mehta, S.A.; Milanov, Z.V.; Velasco, A.M.; Wodicka, L.M.; Patel, H.K.; Zarrinkar, P.P.; Lockhard, D.J. A small moleculekinase interaction map for clinical kinase inhibitors. Nature Biotechn. 2005, 23 (3), 329-336.
229. Nguyen, T.L. Targeting RSK: an overwiew of small molecule inhibitors. Anti-Cancer Agents Med. Chem. 2008, 8, 710-716.
230. Roberts, N.A.; Haworth, R.S.; Avkiran, M. Effects of bisindolylmaleimide PKC inhibitors on p90RSK activity in vitro and in adult ventricular myocytes. Br. J. Pharmacol. 2005, 145 (4), 477-489.
231. Karaman, M.W.; Herrgard, S.; Treiber, D.K.; Gallant, P.; Atteridge, C.T.; Campbell, B.T.; Chan, K.W.; Ciceri, P.; Davis, M.I.; Edeen, P.T.; Faraoni, R.; Floyd, M.; Hunt, J.P.; Lockhard, D.J.; Milanov, Z.V.; Morrison, M.J., Pallares, G.; Patel, H.K.; Pritchard, S.; Wodicka, L.M.; Zarrinkar, P.P. A quantitative analysis of kinase inhibitors selectivity. Nature Biotechn. 2008, 26 (1), 127-132.
232. Smith, J.A.; Poteet-Smith, C.E.; Xu, Y.; Errington, T.M.; Hecht, S.M.; Lannigan, D.A. Identification of the first specific inhibitors of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res. 2005, 65(3), 1027-1034.
233. Sapkota, G.P.; Cummings, L.; Newell, F.S.; Armstrong, C.; Bain, J.; Frodin, M.; Grauert, M.; Hoffmann, M.; Schnapp, G.; Steegmaier, M.; Cohen, P.; Alessi, D.R. BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem. J., 2007, 401(1), 29-38.
234. Cohen, M.S.; Zhang, C.; Shokat, K.M.; Taunton, J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science, 2005, 308(5726), 1318-1321.
235. Balasubramanyam, K.; Varier, R. A.; Altaf, M.; Swaminathan, V.; Siddappa, N.B.; Ranga, U.; Kundu, T. K. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 2004, 279 (49), 51163-51171.
236. Balasubramanyam, K.; Altaf, M.; Varier, R. A.; Swaminathan, V.; Ravindran, A.; Sadhale, P. P.; Kundu, T. K. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J. Biol. Chem. 2004, 279 (32), 33716-33726.
237. Balasubramanyam, K.; Swaminathan, V.; Ranganathan, A.; Kundu, T. K. Small molecule modulators of histone acetyltransferase p300. J. Biol. Chem. 2003, 278 (21), 19134-19140.
238. Stimson, L.; Rowlands, M. G.; Newbatt, Y. M.; Smith, N. F.; Raynaud, F. I.; Rogers, P.; Bavetsias, V.; Gorsuch, S.; Jarman, M.; Bannister, A.; Kouzarides, T.; McDonald, E.; Workman, P.; Aherne, G. W. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol. Cancer Ther. 2005, 4, 1521-1532.
239. Mai, A.; Rotili, D.; Ornaghi, P.; Tosi, F.; Vicidomini, C.; Sbardella, G.; Nebbioso, A.; Altucci, L.; Filetici, P. Identification of small molecules inhibitors of GCN5 histone acetyltransferase activity. ARCIVOC 2006, (8), 28-37.
240. Tan, J.; Cang, S.; Ma, Y.; Petrillo, R.L.; Liu, D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol. 2010, 3(1), 5.
241. Kozikowski, A.P.; Tapadar, S.; Luchini, D.N.; Kim, K.H.; Billadeau, D.D. Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: A new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J. Med. Chem. 2008, 51, 4370-4373.
242. Shein, N.A.; Grigoriadis, N.; Alexandrovich, A.G.; Simeonidou, C.; Lourbopoulos, A.; Polyzoidou, E.; Trembovler, V.; Mascagni, P.; Dinarello, C.A.; Shohami, E. Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB J. 2009, 23(12), 4266-4275.
243. Buggy, J.J.; Cao, Z.A.; Bass K.E.; Verner, E.; Balasubramanian, S.; Liu, L.; Schultz, B.E.; Young, P.R.; Dalrymple, S.A. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol. Cancer Ther. 2006, 5, 1309-1317.
244. Butler, K.V.; Kalin, J.; Brochier, C.; Vistoli, G.; Langley, B.; Kozikowski, A.P. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, Tubastatin A. J. Am. Chem. Soc. 2010, 132(31), 10842-10846.
245. Atadja, P.; Gao, L.; Kwon, P.; Trogani, N.; Walker, H.; Hsu, M.; Yeleswarapu, L.; Chandramouli, N.; Perez, L.; Versace, R.; Wu, A.; Sambucetti, L.; Lassota, P.; Cohen, D.; Bair, K.; Wood, A.; Remiszewski, S. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res. 2004, 64, 689-695.
246. Fournel, M.; Bonfils, C.; Hou, Y.; Yan, P.T.; Trachy-Bourget, M.-C.; Kalita, A.; Liu, J.H.; Lu, A.H.; Zhou, N.Z.; Robert, M.F.; Gillespie, J.; Wang, J.J.; Ste-Croix, H.; Rahil, J.; Lefebvre, S.; Moradei, O.; Delorme, D.; MacLeod, A.R.; Besterman, J.M.; Li, Z.M. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol. Cancer Ther. 2008, 7(4), 759-768.
247. Hu, E.; Dul, E.; Sung, C.M.; Chen, Z.X.; Kirkpatrick, R.; Zhang, G.-F.; Johanson, K.; Liu, R.G.; Lago, A.; Hofmann, G.; Macarron, R.; De Los Frailes, M.; Perez, P.; Krawiec, J.; Winkler, J.; Jaye, M. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther. 2003, 307(2), 720-728.
248. Poellinger, L. Mechanistic aspects - the dioxin (aryl hydrocarbon) receptor. Food Add. Contamin. 2000, 17(4), 261-266.
249. Burbach, K.M.; Poland, A.; Bradfield, C.A. Cloning of the Ahreceptor cDNA reveals a distinctive ligand-activated transcription factor. Proc. Natl. Acad. Sci. U.S.A.1992, 89(17), 8185-8189.
250. Fujita, Y.; Yonehara, M.; Tetsuhashi, M.; Noguchi-Yashide, T.; Hashimoto, Y.; Ishikawa, M. β-Naphthoflavone analogs as potent and soluble aryl hydrocarbon receptor agonists: Improvement of solubility by disruption of molecular planarity. Bioorg. Med. Chem. 2010, 18(3), 1194-1203.
251. Jonsson, M.E.; Frank, D.G.; Woodin, B.R.; Jenny, M.J.; Garrick, R.A.; Behrendt, L.; Hahn, M.E.; Stegeman, J.J. tryptophan photoproduct 6-formylindolo[3,2-b]carbazole (FICZ) binds multiple AHRs and induces multiple CYP1 genes via AHR2 in zebrafish. Chem. Biol. Interact. 2009, 181, 447-454.
252. Gasiewicz, T.A.; Rucci, G. Alpha-naphthoflavone acts as an antagonist of 2,3,7,8-tetrachlorodibenzo-p-dioxin by forming an inactive complex with the Ah receptor. Mol. Pharmacol. 1991, 40, 607-612.
253. Murray, I.A.; Flaveny, C.A.; Chiaro, C.R.; Sharma, A.K.; Tanos, R.S.; Schroeder, J.C.; Amin, S.G.; Bisson, W.H.; Kolluri, S.H.; Perdew, G.H. Suppression of cytokine-mediated complement factor gene expression through selective activation of the Ah receptor with 3′,4′-dimethoxy- α-naphthoflavone. Mol. Pharmacol. 2011, 79, 508-519.
254. Kim, S.H.; Henry, E.C.; Kim, D.K.; Kim, Y,H,; Shin, K.J.; Han, M.S.; Lee, T.G.; Kang, J.K.; Gasiewicz, T.A.; Ryu, S.H.; Suh, P.G. Novel compound 2-methyl-2H-pyrazole-3-carboxylic Acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor. Mol. Pharmacol. 2006, 69, 1871-1878.
255. Murray, I.A.; Morales, J.L.; Flaveny, C.A.; Dinatale, B.C.; Chiaro, C.; Gawdahalli, K.; Amin, S.; Perdew, G.H. Evidence for ligandmediated selective modulation of aryl hydrocarbon receptor activity. Mol. Pharmacol. 2010, 77, 247-254.
256. Murray, I.A.; Krishnegowda, G.; Dinatale, B.C.; Flaveny, C.A.; Chiaro, C.; Lin, J.M.; Sharma, A.K.; Amin, S.; Perdew, G.H. Development of a selective modulator of aryl hydrocarbon (Ah) receptor activity that exhibits anti-inflammatory properties. Chem. Res. Toxicol. 2010, 23, 955-966.
257. Suetsugi, M.; Su, L.; Karlsberg, K.; Yuan, Y.C.; Chen, S. 5,7-Dihydroxy-4′-methoxyisoflavone, flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol. Cancer Res. 2003, 1(13), 981-991.
258. Kallen, J.; Lattmann, R.; Beerli, R.; Blechschmidt, A.; Blommers, M.J.; Geiser, M.; Ottl, J.; Schlaeppi, J.M.; Strauss, A.; Fournier, B. Crystal structure of human estrogen-related receptor alpha in complex with a synthetic inverse agonist reveals its novel molecular mechanism. J. Biol. Chem. 2007, 282(32), 23231-23239.
259. Yang, C.; Chen, S. Two organochlorine pesticides, toxaphene and chlordane, are antagonists for estrogen-related receptor alpha-1 orphan receptor. Cancer Res. 1999, 59(1 8), 4519-4524.
260. Willy, P.J.; Murray, I.R.; Qian, J.; Busch, B.B.; Stevens, W.C.; Martin, R.; Mohan, R.; Zhou, S.; Ordentlich, P.; Wei, P.; Sapp, D.W.; Horlick, R.A.; Heyman, R,A,; Schulman, I.G. Regulation of PPARgamma coactivator 1alpha (PGC-1alpha) signaling by an estrogen-related receptor alpha (ERRalpha) ligand. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(24), 8912-8917.
261. Tremblay, G.B.; Kunath, T.; Bergeron, D.; Lapointe, L.; Champigny, C.; Bader, J.A.; Rossant, J.; Giguère, V. Diethylstilbestrol regulates trophoblast stem cell differentiation as a ligand of orphan nuclear receptor ERR beta. Genes Dev. 2001, 15(7), 833-838.
262. Duellman, S.J.; Calaoagan, J.M.; Sato, B.G.; Fine, R.; Klebansky, B.; Chao, W.R.; Hobbs, P.; Collins, N.; Sambucetti, L.; Laderoute, K.R. A novel steroidal inhibitor of estrogen-related receptor α (ERRα). Biochem. Pharmacol. 2010, 80(6), 819-826.
263. Sui. M.; Zhang, H.; Fan, W. The role of estrogen and estrogen receptors in chemoresistance. Curr. Med. Chem. 2011, 18 (30), 4674-4683.
264. Rosano, C.; Stec-Martyna, E.; Lappano, R.; Maggiolini, M. Structure-based approach for the discovery of novel selective estrogen receptor modulators. Curr. Med. Chem. 2011, 18(8), 1188-1194.